Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
more
Stories about Head and neck cancer
-
Language:
English
- Media:
- Period:
- Period:Total
DEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
moreDEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS
moreDEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS
One documentmoreMerck Advances Oncology Portfolio and Pipeline with New and Long-term Data in Multiple Cancers at ESMO 2020
moreDEBIOPHARM'S IAP ANTAGONIST SIGNIFICANTLY IMPROVES OVERALL SURVIVAL OF HIGH-RISK HEAD & NECK CANCER PATIENTS
moreDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
moreBreakthrough Innovation in Cancer Care From Merck Pipeline to Be Presented at ASCO 2020
moreData From Merck at ASCO 2020 to Showcase Significant Clinical Advances in Cancer Care
moreNorgine B.V. Acquires Azanta A/S, Strengthening Its Position as a Leading European Specialist Pharmaceutical Company
moreERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
moreFDA grants Breakthrough Therapy Designation for Debiopharm's novel chemo-radio sensitizer Debio 1143 for front-line treatment of Head & Neck Cancer
moreEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
moreA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
moreDebiopharm's novel IAP antagonist Debio 1143 achieves outstanding Phase II results for high-risk Head and Neck cancer patients
moreSysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
moreNew Data at ESMO 2019 for Merck Highlight Focused Clinical Development and Commitment to Patient Care
moreCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
moreSpePharm AG Wins Case Against Eisai Inc. in United States District Court for District of Delaware
moreDebiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
moreDebiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
moreMerck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
morePivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
moreFDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
moreMerck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
moreMerck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
moreMerck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
moreBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
more
1